A detailed history of Lord, Abbett & Co. LLC transactions in Merus N.V. stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 395,672 shares of MRUS stock, worth $19.8 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
395,672
Holding current value
$19.8 Million
% of portfolio
0.08%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$39.81 - $60.2 $15.8 Million - $23.8 Million
395,672 New
395,672 $23.4 Million
Q3 2022

Nov 14, 2022

BUY
$18.64 - $28.93 $258,499 - $401,201
13,868 Added 3.39%
422,384 $8.46 Million
Q2 2022

Aug 12, 2022

BUY
$13.98 - $29.25 $198,362 - $415,028
14,189 Added 3.6%
408,516 $9.25 Million
Q1 2022

May 13, 2022

BUY
$23.58 - $30.91 $1.84 Million - $2.42 Million
78,174 Added 24.73%
394,327 $10.4 Million
Q4 2021

Feb 11, 2022

BUY
$20.0 - $32.29 $6.32 Million - $10.2 Million
316,153 New
316,153 $10.1 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.3B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.